Department of Cellular and Molecular Medicine and Center for Biological Research and Center for Biomedical Network Research on Rare Diseases, Madrid, Spain.
Department of Nephrology, Research Institute Hospital 12 de Octubre (imas12), Madrid, Spain.
Kidney Int. 2017 Oct;92(4):953-963. doi: 10.1016/j.kint.2017.03.041. Epub 2017 Jun 19.
IgA nephropathy (IgAN), a frequent cause of chronic kidney disease worldwide, is characterized by mesangial deposition of galactose-deficient IgA1-containing immune complexes. Complement involvement in IgAN pathogenesis is suggested by the glomerular deposition of complement components and the strong protection from IgAN development conferred by the deletion of the CFHR3 and CFHR1 genes (Δ). Here we searched for correlations between clinical progression and levels of factor H (FH) and FH-related protein 1 (FHR-1) using well-characterized patient cohorts consisting of 112 patients with IgAN, 46 with non-complement-related autosomal dominant polycystic kidney disease (ADPKD), and 76 control individuals. Patients with either IgAN or ADPKD presented normal FH but abnormally elevated FHR-1 levels and FHR-1/FH ratios compared to control individuals. Highest FHR-1 levels and FHR-1/FH ratios are found in patients with IgAN with disease progression and in patients with ADPKD who have reached chronic kidney disease, suggesting that renal function impairment elevates the FHR-1/FH ratio, which may increase FHR-1/FH competition for activated C3 fragments. Interestingly, Δ homozygotes are protected from IgAN, but not from ADPKD, and we found five IgAN patients with low FH carrying CFH or CFI pathogenic variants. These data support a decreased FH activity in IgAN due to increased FHR-1/FH competition or pathogenic CFH variants. They also suggest that alternative pathway complement activation in patients with IgAN, initially triggered by galactose-deficient IgA1-containing immune complexes, may exacerbate in a vicious circle as renal function deterioration increase FHR-1 levels. Thus, a role of FHR-1 in IgAN pathogenesis is to compete with complement regulation by FH.
IgA 肾病(IgAN)是一种常见的全球性慢性肾脏病病因,其特征为含半乳糖缺陷 IgA1 的免疫复合物在系膜沉积。补体在 IgAN 发病机制中的作用,可通过补体成分在肾小球沉积以及 CFHR3 和 CFHR1 基因缺失(Δ)对 IgAN 发病的强烈保护作用来提示。在此,我们通过由 112 例 IgAN 患者、46 例非补体相关常染色体显性多囊肾病(ADPKD)患者和 76 例对照个体组成的特征明确的患者队列,来寻找与临床进展相关的因子 H(FH)和 FH 相关蛋白 1(FHR-1)水平之间的相关性。与对照个体相比,IgAN 或 ADPKD 患者的 FH 水平正常,但 FHR-1 水平和 FHR-1/FH 比值异常升高。在疾病进展的 IgAN 患者和已进展至慢性肾脏病的 ADPKD 患者中,FHR-1 水平和 FHR-1/FH 比值最高,这表明肾功能损害会升高 FHR-1/FH 比值,这可能会增加 FHR-1/FH 对活化 C3 片段的竞争。有趣的是,Δ 纯合子可免受 IgAN 的影响,但不能免受 ADPKD 的影响,我们发现 5 例携带 CFH 或 CFI 致病性变异的低 FH 的 IgAN 患者。这些数据支持 IgAN 中由于 FHR-1/FH 竞争或致病性 CFH 变异而导致 FH 活性降低。它们还表明,最初由含半乳糖缺陷 IgA1 的免疫复合物触发的 IgAN 患者的替代途径补体激活,可能会随着肾功能恶化而加剧恶性循环,从而增加 FHR-1 水平。因此,FHR-1 在 IgAN 发病机制中的作用是与 FH 竞争补体调节。